What is Apellis Pharmaceuticals?
Apellis Pharmaceuticals is a complement-focused biopharmaceutical company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Complement-focused biopharmaceutical company
- Headquarters
- Waltham, United States
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: APLS
What is Apellis Pharmaceuticals?
Apellis Pharmaceuticals is a complement-focused biopharmaceutical company company headquartered in Waltham, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Apellis Pharmaceuticals is a complement-focused biopharmaceutical company company headquartered in Waltham, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Apellis Pharmaceuticals should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Apellis Pharmaceuticals offer?
Apellis Pharmaceuticals's profile centers on Complement therapies, Rare diseases, Retina medicines, Clinical development.
- Complement therapies· Complement-focused biopharmaceutical company
- Rare diseases· Complement-focused biopharmaceutical company
- Retina medicines· Complement-focused biopharmaceutical company
- Clinical development· Complement-focused biopharmaceutical company
- Commercial medicines· Complement-focused biopharmaceutical company
- R&D· Complement-focused biopharmaceutical company
How does Apellis Pharmaceuticals make money?
Apellis Pharmaceuticals makes money through commercial activity tied to complement-focused biopharmaceutical company.
Apellis Pharmaceuticals monetizes through the model common to complement-focused biopharmaceutical company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Apellis Pharmaceuticals?
Apellis Pharmaceuticals's named executives should be verified on the official leadership or investor-relations page before outreach.
- Apellis Pharmaceuticals executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Apellis Pharmaceuticals finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Apellis Pharmaceuticals operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Apellis Pharmaceuticals's leadership?
Apellis Pharmaceuticals should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://apellis.com- Apellis Pharmaceuticals investor relationsInvestor relations / corporate contactcontact via https://apellis.com
- Apellis Pharmaceuticals sales or partnershipsCommercial contact routecontact via https://apellis.com
- Apellis Pharmaceuticals media relationsMedia or communications contact routecontact via https://apellis.com
How is Apellis Pharmaceuticals funded?
Apellis Pharmaceuticals's current status is Public company; Nasdaq: APLS.
Apellis Pharmaceuticals's capital profile is best understood through its current public-company status: Public company; Nasdaq: APLS. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Apellis Pharmaceuticals get here?
Apellis Pharmaceuticals's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingApellis Pharmaceuticals is foundedThe company begins building in complement-focused biopharmaceutical company.
- Scale-upCommercial footprint expandsApellis Pharmaceuticals broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: APLSPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Apellis Pharmaceuticals's competitors?
Apellis Pharmaceuticals competes with larger incumbents and focused specialists in complement-focused biopharmaceutical company.
Apellis Pharmaceuticals — frequently asked questions
